Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-04-06
ICR Author
Marsden,
Author
Hiwarkar, P
Amrolia, P
Sivaprakasam, P
Lum, SH
Doss, H
O’Rafferty, C
Petterson, T
Patrick, K
Silva, J
Slatter, M
Lawson, S
Rao, K
Steward, C
Gassas, A
Veys, P
Wynn, R
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Key Points Brincidofovir has superior antiadenoviral activity and safety profile compared with cidofovir. Brincidofovir is highly efficacious in controlling adenoviremia during the lymphopenic phase of HCT.
URI
https://repository.icr.ac.uk/handle/internal/1534
DOI
https://doi.org/10.1182/blood-2016-11-749721
Collections
  • Other ICR Research
Language
eng
License start date
2017-04-06
Citation
Blood, 2017, 129 (14), pp. 2033 - 2037
Publisher
American Society of Hematology

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.